279 selected questions connect practical review points to their actual local source cards. This is not a complete safety checklist, patient-specific dosing engine or approval score.
A label and a professional guideline may differ. A different formulation or indication may only appear to conflict. Read the complete stored source, its date, renal measure, population and qualifications. These new interpretations remain pending independent clinical review.
Find a review question
Use drug/source terms only, never patient identifiers. Filters are in the URL. No JavaScript is required. CSV includes all matches, not just this page.
13 matching checks; page 2 of 2.
Guideline difference | Added v5.0
Is active-vitamin-D treatment indicated before selecting the label dose?
The capsule label provides dosing once treatment is chosen. KDIGO discourages routine active vitamin D in adults with nondialysis CKD G3a-G5, reserving it for selected G4-G5 severe progressive hyperparathyroidism. This is a treatment-selection qualification, not a conflicting dose calculation.
What to check
Assess trends and modifiable factors before choosing therapy; do not transfer this nondialysis qualification to all dialysis patients.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Guideline difference | Added v5.0
Which named source is controlling the regimen, and has the difference been adjudicated?
Polymyxin B - systemic injection
The RX mirror calls for renal reduction. UNMC recommends no loading or maintenance reduction for renal impairment or CRRT, citing international consensus. These recommendations are not silently harmonized.
What to check
Request infectious-disease/pharmacy adjudication, document the chosen source and monitor toxicity. Do not construct a hybrid dose from opposing instructions.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Guideline difference | Added v4.5
Is an old sofosbuvir restriction or a ribavirin rule being applied to the wrong regimen?
Sofosbuvir / velpatasvir - EPCLUSA
AASLD-IDSA records the 2019 regulatory change for sofosbuvir in severe kidney disease/dialysis. Its DAA no-adjustment recommendation does not apply automatically to ribavirin or resolve every liver/renal combined evidence gap.
What to check
Do not reuse a historical blanket severe-renal exclusion. Match the complete HCV regimen, hepatic status and any ribavirin requirement.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Before using a source
Confirm exact product and route, indication, age/weight, renal estimate and units, changing renal function, dialysis modality and timing, interacting medicines, monitoring, and the applicable institution's review. A successful page retrieval or a source-count badge establishes none of these on its own.